Previous close | 32.75 |
Open | 32.86 |
Bid | 32.96 x 51100 |
Ask | 32.98 x 25600 |
Day's range | 32.85 - 33.12 |
52-week range | 21.14 - 35.47 |
Volume | |
Avg. volume | 2,318,422 |
Market cap | 48.79B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 32.63 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.30 (0.90%) |
Ex-dividend date | 08 May 2024 |
1y target est | N/A |
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.